As per the agreement, Vertex will utilise Bend’s formulation development and manufacturing services for specific projects and clinical trials, with the goals of both enhancing the delivery of Vertex compounds and supporting the progression of certain Vertex product candidates through clinical development.
The collaboration is designed to leverage the fundamental scientific capabilities of each company to solve formulation and process-development challenges and to produce commercial drug products that are optimised for therapeutic benefit.
Peter Mueller, EVP of global research and development and chief scientific officer, said: “Our collaboration with Bend Research exemplifies Vertex’s commitment to the treatment of serious diseases through cutting-edge science and innovative technologies.”